From genetic risk screening to early cancer detection, omics innovation is improving how we analyze and utilize biological information.
Companies involved in the capture, sequencing, and analysis of biological data are transforming healthcare, from disease detection with AI to treatment via precision medicine. The “omics” sector spans genomic, transcriptomic, proteomic, and metabolomic data, and includes companies like Karius, which aims to help clinicians detect diseases earlier, and Genome Medical, which helps patients better understand their specific genetic risks.
In recent years, new companies have emerged to leverage omics in every part of the patient journey. Stakeholders across the healthcare ecosystem are using these technologies and more to improve patient outcomes and bring down costs in the process.
The Covid-19 pandemic has further amplified the role of omics in the healthcare system, as rapid sequencing and personalized treatment have become paramount in the fight against the virus.
Using the CB Insights platform, we identified 60+ private omics companies and mapped them according to 8 categories within the space, from genetic risk screening to drug development.
This market map consists of private, active companies only and is not intended to be exhaustive of the space. Categories are not mutually exclusive, and companies are mapped according to primary use case.
Please click to enlarge.